Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person’s chance ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...